Hangzhou Ausia Biological Technology

Hangzhou Ausia Biological Technology is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative long-acting peptide and protein therapeutics. The company utilizes its proprietary technology platforms to address significant unmet needs in metabolic diseases, particularly type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH). Their lead programs include multi-target agonists that synchronize the activation of GLP-1, GIP, and glucagon receptors to achieve superior weight loss and glycemic control. Beyond its internal pipeline, Ausia offers specialized CDMO services for peptide synthesis and recombinant protein production to global partners. The company is headquartered in Hangzhou, China, where it operates R&D laboratories and GMP-compliant manufacturing facilities. Ausia's leadership team brings extensive experience from global pharmaceutical companies, driving a strategy of both internal innovation and external collaboration.